All In Biotech

Drug Trial Radar · NCT03640481

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

159

Actual

Start

Oct 11, 2018

Primary completion

Dec 11, 2023

Study completion Dec 11, 2023

Sponsor

Lead sponsor
Kadmon, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Aug 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy

Conditions

  • Chronic Graft-versus-host-disease

Interventions

  • Belumosudil (KD025)Drug

    Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital Site Number : 154

    Phoenix, Arizona

  • University of Arizona - Cancer Center Site Number : 122

    Tucson, Arizona

  • City of Hope Medical Center Site Number : 050

    Duarte, California

  • University of California, Los Angeles (UCLA) - Medical Center Site Number : 104

    Los Angeles, California

  • University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center Site Number : 058

    San Francisco, California

  • Stanford Cancer Center Site Number : 108

    Stanford, California

  • Colorado Blood Cancer Institute Site Number : 098

    Denver, Colorado

  • University of Miami - Sylvester Cancer Center Site Number : 097

    Miami, Florida

  • Moffitt Site Number : 102

    Tampa, Florida

  • Emory University School of Medicine Site Number : 100

    Atlanta, Georgia

  • Augusta University Medical Center Site Number : 093

    Augusta, Georgia

  • University of Illinois at Chicago Site Number : 139

    Chicago, Illinois

  • University of Iowa Site Number : 126

    Iowa City, Iowa

  • University of Kansas Cancer Center Site Number : 105

    Fairway, Kansas

  • Center for Cancer Research National Cancer Institute Site Number : 107

    Bethesda, Maryland

  • Massachusetts General Hospital Site Number : 002

    Boston, Massachusetts

  • Dana-Farber Cancer Institute Site Number : 004

    Boston, Massachusetts

  • CS Mott Children's Hospital Site Number : 157

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Institute-4100 John R St Site Number : 094

    Detroit, Michigan

  • University of Minnesota Site Number : 051

    Minneapolis, Minnesota

  • Washington University School of Medicine Site Number : 125

    St Louis, Missouri

  • University of Rochester Site Number : 106

    Rochester, New York

  • Wake Forest Site Number : 123

    Winston-Salem, North Carolina

  • The Cleveland Clinic Foundation Site Number : 041

    Cleveland, Ohio

  • James Cancer Hospital & Wexner Medical Center at the Ohio State University Comprehensive Cancer Center Site Number : 103

    Columbus, Ohio

  • Oregon Health & Science University (OHSU) Site Number : 095

    Portland, Oregon

  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132

    Pittsburgh, Pennsylvania

  • Sarah Cannon and HCA Research Institute Site Number : 007

    Nashville, Tennessee

  • Vanderbilt University Medical Center Site Number : 063

    Nashville, Tennessee

  • South Austin Medical Center Site Number : 091

    Austin, Texas

  • MD Anderson Cancer Center Site Number : 057

    Houston, Texas

  • Texas Transplant Institute Site Number : 079

    San Antonio, Texas

  • Fred Hutchinson Cancer Research Center Site Number : 052

    Seattle, Washington

  • University of Wisconsin - Carbone Cancer Center Site Number : 135

    Madison, Wisconsin

  • Froedtert Hospital and the Medical College of Wisconsin Site Number : 101

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.